Abstract： Objective To investigate the effect of recombinant human brain natriuretic peptide(rhBNP)combined with Milrinone in emergency patients with congestive heart failure(CHF).Methods 94 emergency patients with CHF admitted to Pingxiang People's Hospital from September 2021 to October 2023 were retrospectively analyzed,and divided into 2 groups according to different treatment methods,with 47 cases each.The control group was treated with milrinone and the observation group were treated with rhBNP combined with milrinone.The clinical efficacy,serological indexes,cardiac function indexes,ventricular remodeling indexes and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate,left ventricular ejection fraction,stroke output and left ventricular mass index in observation group were higher than those in control group.N-terminal brain natriuretic peptide precursor,angiotensin Ⅱ,aldosterone,plasma renin activity,hypersensitive C-reactive protein,interleukin-6,tumor necrosis factor-α,left ventricular end-systolic diameter,left ventricular end-diastolic diameter,posterior left ventricular wall thickness and diastolic ventricular septal thickness were lower than those of control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion rhBNP combined with milrinone can enhance the therapeutic effect of emergency CHF,improve cardiac function and serological indexes,and promote ventricular remodeling with less adverse reactions.